PetMed Express (PETS)

The business focuses primarily on retail consumers in the United States. Its product range includes flea and tick treatments, heartworm preventatives, pain and arthritis medications, skin and allergy products, nutritional supplements, and other pet wellness items. Prescription orders generally require veterinary authorization, while non-prescription products are sold through the company’s online and direct marketing channels.

PetMed Express operates in a competitive pet care market that includes veterinary practices, online retailers, big-box chains, supermarkets, and specialty pet stores. Its appeal rests on convenience, brand recognition, home delivery, recurring purchases, and a customer base that includes pet owners who regularly need preventive medications. The company’s revenue is generated mainly from sales of pet medications and related supplies rather than from veterinary services.

The broader pet health market benefits from long-term trends such as pet humanisation, higher spending on companion animals, and demand for easier access to medications. At the same time, PetMed Express faces pressure from price competition, customer acquisition costs, manufacturer distribution policies, and changing consumer shopping habits. For investors, PETS offers exposure to the pet medication and wellness category through a pharmacy-led e-commerce model.